Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Implantable Defibrillator Could Present More Cardiac Problems for Some Patients



When ICDs detect an abnormal heart rhythm, they deliver a small shock to the muscle in order to mitigate the risk of sudden cardiac death.

Share this!

February 17, 2017 | by Sarah Hand, M.Sc.

According to a new study published in the journal, Circulation: Cardiovascular Quality and Outcomes, patients who receive a shock from an implantable cardioverter defibrillator (ICD) could require further medical attention for cardiac issues. The researchers found that this was true regardless of whether the shock was medically necessary, calling into question the safety of some of these devices.

When ICDs detect an abnormal heart rhythm, they deliver a small shock to the muscle in order to mitigate the risk of sudden cardiac death. However, ICDs can mistake normal changes in heart rhythm with a ventricular arrhythmia, administering inappropriate shocks that could be damaging.

“ICDs cannot assess patients the way a doctor can,” Dr. Mintu Turakhia, Cardiac electrophysiologist and senior director of research and innovation at the Center for Digital Health at Stanford University in California, told Medical News Today. “The device doesn't know, for instance, if the patient is unconscious or has a pulse. We wanted to see what happens after a shock, in terms of care and cost, to help define the potential benefit of smarter ways to program these devices.”

Between 2008 and 2010, the study authors compared data collected from the ICD medical devices implanted in 10,266 patients with their healthcare records. A total of 963 patients experienced 1,885 shocks during the study period, with 38 percent of those shocks determined to be administered inappropriately.

The researchers also found that 46 percent of those patients who received a shock required additional healthcare following the event. After both appropriate and inappropriate shocks, patients were often treated using invasive cardiovascular procedures, including cardiac catheterization and electrophysiology.

About 33 percent of patients who received a shock were treated in the emergency room or outpatient care, while one in seven patients were admitted to the hospital for further treatment and observation. The average cost of these healthcare procedures following an appropriate shock was $5,592, while healthcare following an inappropriate shock cost $4,470.

“Obviously, shocks that save people's lives are a good thing, but they are also very painful, can be traumatic and often lead to more healthcare procedures and expenses,” said Turakhia. “This is why strategies to make these ICDs more selective so that they deliver fewer inappropriate shocks is especially important. Fortunately, the industry has made many advancements in this area.”

Newer-model ICDs have improved programming meant to reduce the number of inappropriate shocks. According to Turakhia, clinicians can chose to program newer medical devices to offer delayed shocks after the ICD has detected an arrhythmia, to allow the heart some time to correct itself.

“From this study, we cannot tell whether any patient received appropriate or inappropriate care - only whether they received an appropriate shock or not,” said Turakhia. “We can say, however, that the costs associated with both kinds of shock are substantial and that optimal device programming that reduce shock events are likely to decrease healthcare costs and improve patient health.”

Keywords: Medical Device, Healthcare, Cardiology


Share this with your colleagues!

New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News

Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News

Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


Top 5 Most Impactful Tweets from #AAIC17


Into the Great Wide Open: PTC’s Transformation & Global Journey to Bring Patients a First Ever Rare Disease Therapy

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.